8-K: LivaNova's VNS Therapy Reimbursement Maintained by CMS Despite Disappointment

The U.S. Centers for Medicare and Medicaid Services (CMS) will maintain the current reimbursement level for LivaNova's VNS Therapy for drug-resistant epilepsy (DRE), a decision the company is disappointed with but does not expect to impact its business.

Summary

• The U.S. Centers for Medicare and Medicaid Services (CMS) has decided to maintain the current reimbursement level for LivaNova's VNS Therapy for drug-resistant epilepsy (DRE) under the 2025 Medicare Hospital Outpatient Prospective Payment System.
• This means VNS Therapy will remain at the Level 5 Neurostimulator and Related Procedures Ambulatory Payment Classification (APC).
• LivaNova has expressed disappointment with this decision.
• Despite the disappointment, LivaNova does not anticipate any negative impact on its business.
• The company will continue to seek further reimbursement opportunities for VNS Therapy for DRE.

Sentiment

Score: 5

Explanation: The sentiment is neutral to slightly negative. While the company states the decision won't impact the business, they also express disappointment, indicating a less than ideal outcome.

Positives

• The current reimbursement level for VNS Therapy has been maintained by CMS.
• LivaNova does not anticipate any negative impact on its business from this decision.
• LivaNova will continue to pursue reimbursement opportunities for VNS Therapy for DRE.

Negatives

• LivaNova is disappointed with the CMS decision to maintain the current reimbursement level.

Risks

• The company may face challenges in securing higher reimbursement rates for VNS Therapy in the future.
• Continued reliance on the current reimbursement level could limit potential revenue growth.

Future Outlook

LivaNova will continue to pursue reimbursement opportunities for VNS Therapy for DRE.

Management Comments

• LivaNova is disappointed by the CMS decision.
• LivaNova does not believe that this decision will impact the business.

Industry Context

This announcement is relevant to the medical device industry, particularly companies involved in neurostimulation therapies and those reliant on Medicare reimbursement policies. The decision highlights the ongoing challenges in securing favorable reimbursement rates for innovative medical technologies.

Comparison to Industry Standards

• The decision by CMS to maintain the current reimbursement level for VNS Therapy is consistent with the challenges faced by other medical device companies seeking higher reimbursement rates for their products.
• Companies like Medtronic, which also offer neurostimulation therapies, face similar hurdles in navigating the complexities of Medicare reimbursement policies.
• The Level 5 APC classification is a standard reimbursement level for neurostimulator procedures, and LivaNova's VNS Therapy is being treated similarly to other comparable devices.

Stakeholder Impact

• Shareholders may be concerned about the lack of progress in securing higher reimbursement rates.
• Patients may not see any immediate change in access to VNS Therapy.
• Employees may be unaffected by this decision.

Next Steps

• LivaNova will continue to pursue reimbursement opportunities for VNS Therapy for DRE.

Key Dates

Keywords

VNS Therapy, LivaNova, CMS, reimbursement, drug-resistant epilepsy, DRE, Medicare, neurostimulator, APC